The present invention relates to chimeric proteins comprising a consensus interferon as a signaling agent. In some embodiments, the consensus interferon is modified and comprises one or more mutations. In an embodiment, the modified consensus interferon comprise one or more mutations that reduce its affinity for IFNAR1 and comprises one or more mutations that reduce its affinity for IFNAR2. The present invention provides pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases. The present invention relates to a method for treating cancer, comprising administering an effective amount of the chimeric protein.La présente invention concerne en partie des protéines chimères comprenant un interféron de consensus ou un variant de ce dernier et leur utilisation en tant qu'agents thérapeutiques.
